<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04909983</url>
  </required_header>
  <id_info>
    <org_study_id>DPLX-PT01</org_study_id>
    <nct_id>NCT04909983</nct_id>
  </id_info>
  <brief_title>An Explorative Study of Treatment of Contact Dermatitis Due to DiabetesDevices</brief_title>
  <official_title>A Single Center Explorative Study of the Treamtent ofDiabetes Patients With Contact Dermatitits Caused byInsulin Infusion Pump or Glucose Monitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Copenhagen University Hospital at Herlev</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Copenhagen University Hospital at Herlev</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A feasibility study of treatment with a occlusive medical device or patch in pediatric&#xD;
      patients with type 1 diabetes suffering from irritative contact dermatitis due to diabetes&#xD;
      devices.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 19, 2021</start_date>
  <completion_date type="Anticipated">October 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate of active treatment versus standard of care</measure>
    <time_frame>8 days after active treatment compared to 8 days after standard of care</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of Irritative contact dermatitis</measure>
    <time_frame>After 8 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Contact Dermatitis Irritant</condition>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medical Device, an occlusive patch for 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of Care</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DPLX-PT1</intervention_name>
    <description>A polymer skin patch for occlusional therapy</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control arm</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent, and for patients under the legal age consent by a legal&#xD;
             guardian&#xD;
&#xD;
          -  Clinically confirmed, active and evaluable irritant contact dermatitis (ICD)&#xD;
&#xD;
          -  Age 6-20 at the time of signing the informed consent form (ICF)&#xD;
&#xD;
          -  Ability to answer study questionnaires&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any type of skin irritation other than ICD&#xD;
&#xD;
          -  Use of occlusive therapy for the treatment of their ICD, or unwilling to refrain from&#xD;
             this treatment for duration of study&#xD;
&#xD;
          -  For any other reason considered unsuitable by the investigator&#xD;
&#xD;
          -  Pregnant or of child-bearing potential unwilling to use acceptable effective&#xD;
             contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Korsgaard Berg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric Department, Herlev Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Korsgaard Berg, MD</last_name>
    <phone>+4522393590</phone>
    <email>anna.korsgaard.berg.02@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jannet Svensson, MD, PhD</last_name>
    <phone>+4538681089</phone>
    <email>jannet.svensson@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pediatric Department, Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Korsgaard Berg, MD</last_name>
      <phone>+4522393590</phone>
      <email>anna.korsgaard.berg.02@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Anna Korsgaard Berg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 20, 2021</study_first_submitted>
  <study_first_submitted_qc>June 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2021</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Copenhagen University Hospital at Herlev</investigator_affiliation>
    <investigator_full_name>Anna Korsgaard Berg</investigator_full_name>
    <investigator_title>Principal Investigator MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Contact</mesh_term>
    <mesh_term>Dermatitis, Irritant</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

